Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys' Q2 Revenue Grows 42 Percent Though Profit Turns to Loss

NEW YORK (GenomeWeb News) – MorphoSys today reported a net loss for the second quarter although revenue grew 47 percent.
Receipts for the three months ended June 30 increased to $11.7 million from $7.9 million year over year.
R&D costs increased 24 percent to $4 million from $3 million from the comparable quarter a year ago.
MorphoSys reported a net loss of 400,000 for the quarter, compared to a net profit of $1.3 million during the comparable period last year.
As reported yesterday in GenomeWeb News, MorphoSys raised its revenue guidance for 2006 to $52 million from $50 million.
MorphoSys's said it had around $1.6 million in cash and cash equivalents as of June 30.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.